Metformin vs. Ozempic: Weight Loss, Cost, and Whether to Take Both

Metformin vs Ozempic: which one actually helps you lose weight?

There's no trial that put these two drugs head-to-head in the same study, so any comparison here is really two separate bodies of research placed side by side — worth saying plainly before the numbers do the rest of the talking. Semaglutide, the active ingredient in Ozempic, was tested at its full weight-management dose in the STEP 1 trial, where participants lost close to 15% of their body weight on average over 68 weeks. Ozempic itself is approved at a lower ceiling than that trial dose, so real-world results from Ozempic prescribed off-label for weight loss tend to land below that headline figure, even though it's the same molecule.

Metformin has never produced anything in that range on its own. Across the trials that have measured it — mostly in women with PCOS or type 2 diabetes, rarely in the exact population asking this question — the average effect is modest: a few pounds at most, and a fair number of studies find metformin essentially weight-neutral when used by itself, with the benefit only showing up clearly when it's paired with diet changes. That's not a knock on the drug. It simply wasn't built or tested to move weight the way an appetite-suppressing GLP-1 was.

What each drug does for blood sugar and insulin resistance

Metformin is a biguanide, approved by the FDA in the mid-1990s, and it works almost entirely on the supply side of blood sugar. It tells the liver to release less glucose into the bloodstream, and it makes muscle and fat cells more responsive to the insulin you already have — which is a fairly direct description of what 'improving insulin resistance' means in practice. Because it doesn't push the pancreas to release extra insulin, it rarely causes low blood sugar on its own, which is part of why it's tolerated well enough to prescribe broadly.

Ozempic works on a completely different lever. Semaglutide mimics GLP-1, a hormone your gut already makes after eating, and it tells the pancreas to release insulin specifically when blood sugar is high, slows how fast your stomach empties, and quiets appetite signaling in the brain. Approved by the FDA in 2017, strictly for type 2 diabetes. Where metformin adjusts the machinery already running in the background, Ozempic changes how much you eat and how your body responds once you have.

Can you take metformin and Ozempic together?

Yes — and it's a far more established pattern than the marketing around either drug usually suggests. Several of the pivotal trials that led to Ozempic's own FDA approval, including the SUSTAIN 2, 3, 4, and 10 studies, enrolled patients who were already taking metformin and kept them on it throughout. A meaningful share of the safety and efficacy evidence behind semaglutide comes from people using both drugs at the same time, not one instead of the other.

Practically, this shows up as prescribers keeping metformin as the steady daily baseline for insulin sensitivity while adding a GLP-1 on top for appetite and weight — rather than stopping one to start the other. Because metformin carries very little hypoglycemia risk by itself, the combination is generally well tolerated on that front specifically. What each drug adds to your own GI side-effect load is a separate question, covered below, and it's the one worth discussing with whoever is managing your prescriptions rather than assuming the combination is automatically easy.

How much does each one cost — and why is the gap so big?

The table above lines up every pathway; the short version is that metformin is close to the cheapest prescription drug in the country, and Ozempic is close to the most expensive. Metformin has been a generic, multi-manufacturer commodity for decades, which is exactly why Walmart can sell it through its $4 generics list. A GoodRx coupon typically lands the immediate-release version well under $15 a month at major chains. The extended-release version, sold as Glucophage XR or its generics, costs more at every pharmacy — but is still a fraction of any GLP-1's price.

Insurance barely changes the metformin math, because there's so little room left to move: it sits on the lowest generic tier of nearly every US formulary. Insurers essentially don't bother restricting a drug this cheap.

Ozempic is the opposite story, because it's a patented, brand-only injectable that Novo Nordisk prices on its own terms, and insurance coverage is tightly tied to the type-2-diabetes label. Full retail without any program runs over $1,000 a month. NovoCare's own self-pay program brings that down considerably, with the oral tablet the cheapest entry point and the injection settling higher at maintenance dose. The real floor is the NovoCare Savings Card — it can bring a commercially insured, type-2-diabetes-labeled prescription down to just $25 a month, a tier a weight-loss-only or PCOS-only prescription generally can't reach, regardless of how good the rest of your insurance is. Our full Ozempic cost breakdown walks through every pathway, including compounded semaglutide, in more depth than fits here.

Side effects: metformin's stomach issues vs Ozempic's GI symptoms

Both drugs cause gastrointestinal side effects, but they show up differently. Metformin's are mostly a first-weeks problem: diarrhea, nausea, and a metallic taste are the most common complaints, and they typically ease as your body adjusts — switching from immediate-release to the extended-release version often helps for people who don't tolerate the standard tablet well. The rare but serious risk is lactic acidosis, tied specifically to reduced kidney function; the FDA advises against starting metformin when eGFR falls between 30 and 45 mL/min/1.73m² and contraindicates it entirely below 30, which is why a basic kidney-function check is a standard part of starting the drug. Reported incidence of lactic acidosis is low, but it's the reason metformin isn't a start-and-forget prescription for everyone.

Ozempic's GI symptoms — nausea, occasional vomiting, diarrhea, and constipation — trace back to the same slowed-digestion mechanism that makes it effective, and roughly one in five people notice nausea at some point during treatment, usually worst right after a dose increase. The fuller picture of Ozempic's side effects, including what's temporary and what warrants a same-day call to your provider, is worth reading before starting either drug, since layering a GLP-1 on top of metformin means accounting for both symptom profiles at once, not just the newer one.

Who can actually get prescribed each one? Access, off-label use, insurance

This is where the asymmetry between these two drugs really shows up, and it's arguably a bigger factor than the science for a lot of women deciding where to start. Metformin is FDA-approved for type 2 diabetes, but it's been prescribed off-label for insulin resistance and PCOS for decades — there's no FDA-approved medication for PCOS specifically, and metformin has become a default first step in that gap because it's cheap, well understood, and requires only a routine visit and basic labs to check kidney function before starting. A prescriber rarely hesitates to write it, and insurers rarely bother fighting a drug this inexpensive.

Ozempic is a different conversation. It's approved only for type 2 diabetes, so using it for weight-related insulin resistance or PCOS without that diagnosis is off-label, and it's a use insurers actively push back on — a chart that says 'insulin resistance' or 'PCOS' instead of 'type 2 diabetes' commonly gets denied when the plan reviews the prescription. That's the direct result of a drug that costs over $1,000 a month at retail triggering far more scrutiny than one that costs $4.

Does this play out differently for PCOS-related weight gain or perimenopause insulin resistance specifically?

Falling, fluctuating estrogen in perimenopause worsens insulin resistance on its own and tends to shift fat storage toward the abdomen — a mechanism covered in full in what actually causes perimenopause weight gain. For a woman who's carried PCOS-related insulin resistance into her forties, that hormonal shift often makes an existing pattern worse rather than introducing a new one, which is exactly the scenario where a prescriber reaches for metformin first: it has the longest track record in this specific population, with decades of use aimed at improving insulin markers and menstrual regularity in PCOS.

GLP-1 research in PCOS specifically is newer and thinner. Most of the completed trials pairing a GLP-1 with metformin in PCOS used liraglutide, an older GLP-1, rather than semaglutide — those trials generally found the combination outperformed metformin alone on weight and insulin markers. Semaglutide-specific research in women with PCOS and obesity is now underway but not yet complete, so it's honest to say the evidence base for combining metformin with Ozempic specifically in PCOS is still catching up to the clinical practice of doing it.

Which one is right for you? Verdict by profile

• You have insulin resistance or PCOS without a type 2 diabetes diagnosis, and cost is a real constraint: metformin is the realistic starting point — cheap, well-tolerated by most people, and the drug your prescriber can write today without an insurance fight.
• Your main goal is meaningful weight loss, not just steadier blood sugar: Ozempic (or its on-label weight-management sibling, Wegovy) has the stronger evidence for that specific outcome — metformin alone isn't built to get you there.
• Your prescriber has suggested both: that's a legitimate, evidence-supported plan, not a sign that metformin 'isn't working' — many GLP-1 trials were run on top of background metformin therapy for exactly this reason.
• You have reduced kidney function: metformin needs a dose adjustment or may be off the table depending on your eGFR — this is a conversation for your prescriber before starting, not after.
• Metformin's stomach side effects have been hard to tolerate: ask about the extended-release version before ruling the drug out entirely; if it still doesn't work, that's a real reason to discuss other options, GLP-1s included.
• You're not sure medication is the right next step yet: the full order of operations for perimenopause weight loss — what to try before any prescription, and when medication actually earns its place — is worth reading first.